Characteristics | Number of patients (%) |
---|---|
Total | 11 (11/47, 23.4%) |
Type of thromboembolic disease | |
Venous | 9 (81) |
Arterial | 0 (0) |
Both venous and arterial | 2 (19) |
Patients’ situation | |
Ambulatory | 5 (45) |
Hospitalized | 6 (55) |
Time of occurrence | |
Before starting treatment | 7 (63) |
During treatment | 4 (37) |
Situation of occurrence of TEEs | |
Symptomatic | 10 (91) |
Incidental | 1 (9) |
Time of occurrence according to the clinical situation of the disease | |
Untreated | 7 (63) |
During platinum-based chemotherapy | 2 (28) |
During immune checkpoint therapy | 1 (9) |
During ROS1 TKIs treatment | 1 (9) |
Time of occurrence according to the clinical situation of the disease | |
Untreated | 7 (63) |
Partial response | 0 (0) |
Stable disease | 2 (18) |
Progressive disease | 2 (18) |
Location of TEEs | |
Only VTE | |
a) Only deep vein thrombosis (DVT) | 3 (27) |
Lower extremity DVT | 2 (67) |
Upper extremity DVT | 1 (33) |
Lower extremity and upper extremity DVT | 0 (0) |
b) Only pulmonary embolism (PE) | 1 (9) |
c) DVT and PE combined | 5 (45) |
Lower extremity DVT and PE | 3 (60) |
Upper extremity DVT and PE | 1 (20) |
Lower extremity, upper extremity DVT and PE | 1 (20) |
Both ATE and VTE | 2 (28) |
a) Stroke and DVT | 1 (50) |
b) Stroke and PE | 1 (50) |
Recurrent TEEs | |
Yes | 5 (45) |
under therapeutic anticoagulation | 5 (100) |
not under therapeutic anticoagulation | 0 (0) |
No | 6 (55) |
First-line anti-tumor treatment in patients with TEEs recurrence | |
During chemotherapy | 3 (3/4, 75%) |
During ROS1 TKIs treatment | 2 (2/6, 33%) |
Anticoagulation therapy | |
Low molecular weight heparin | 8 (73) |
Novel oral anticoagulant | 3 (27) |